200 related articles for article (PubMed ID: 17876041)
1. Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: induction of chemopreventive mechanisms.
Yu B; Dietz BM; Dunlap T; Kastrati I; Lantvit DD; Overk CR; Yao P; Qin Z; Bolton JL; Thatcher GR
Mol Cancer Ther; 2007 Sep; 6(9):2418-28. PubMed ID: 17876041
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.
Overk CR; Peng KW; Asghodom RT; Kastrati I; Lantvit DD; Qin Z; Frasor J; Bolton JL; Thatcher GR
ChemMedChem; 2007 Oct; 2(10):1520-6. PubMed ID: 17654759
[TBL] [Abstract][Full Text] [Related]
3. Structural modulation of oxidative metabolism in design of improved benzothiophene selective estrogen receptor modulators.
Qin Z; Kastrati I; Ashgodom RT; Lantvit DD; Overk CR; Choi Y; van Breemen RB; Bolton JL; Thatcher GR
Drug Metab Dispos; 2009 Jan; 37(1):161-9. PubMed ID: 18936111
[TBL] [Abstract][Full Text] [Related]
4. Chemical modification modulates estrogenic activity, oxidative reactivity, and metabolic stability in 4'F-DMA, a new benzothiophene selective estrogen receptor modulator.
Liu H; Bolton JL; Thatcher GR
Chem Res Toxicol; 2006 Jun; 19(6):779-87. PubMed ID: 16780356
[TBL] [Abstract][Full Text] [Related]
5. Uterine peroxidase-catalyzed formation of diquinone methides from the selective estrogen receptor modulators raloxifene and desmethylated arzoxifene.
Liu H; Qin Z; Thatcher GR; Bolton JL
Chem Res Toxicol; 2007 Nov; 20(11):1676-84. PubMed ID: 17630709
[TBL] [Abstract][Full Text] [Related]
6. Bioactivation of the selective estrogen receptor modulator desmethylated arzoxifene to quinoids: 4'-fluoro substitution prevents quinoid formation.
Liu H; Liu J; van Breemen RB; Thatcher GR; Bolton JL
Chem Res Toxicol; 2005 Feb; 18(2):162-73. PubMed ID: 15720120
[TBL] [Abstract][Full Text] [Related]
7. Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity.
Qin Z; Kastrati I; Chandrasena RE; Liu H; Yao P; Petukhov PA; Bolton JL; Thatcher GR
J Med Chem; 2007 May; 50(11):2682-92. PubMed ID: 17489582
[TBL] [Abstract][Full Text] [Related]
8. Raloxifene and desmethylarzoxifene block estrogen-induced malignant transformation of human breast epithelial cells.
Kastrati I; Edirisinghe PD; Hemachandra LP; Chandrasena ER; Choi J; Wang YT; Bolton JL; Thatcher GR
PLoS One; 2011; 6(11):e27876. PubMed ID: 22140478
[TBL] [Abstract][Full Text] [Related]
9. SERMs attenuate estrogen-induced malignant transformation of human mammary epithelial cells by upregulating detoxification of oxidative metabolites.
Hemachandra LP; Patel H; Chandrasena RE; Choi J; Piyankarage SC; Wang S; Wang Y; Thayer EN; Scism RA; Michalsen BT; Xiong R; Siklos MI; Bolton JL; Thatcher GR
Cancer Prev Res (Phila); 2014 May; 7(5):505-15. PubMed ID: 24598415
[TBL] [Abstract][Full Text] [Related]
10. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.
Park WC; Jordan VC
Trends Mol Med; 2002 Feb; 8(2):82-8. PubMed ID: 11815274
[TBL] [Abstract][Full Text] [Related]
11. Selective estrogen receptor modulators: mechanism of action and clinical experience. Focus on raloxifene.
Thiebaud D; Secrest RJ
Reprod Fertil Dev; 2001; 13(4):331-6. PubMed ID: 11800172
[TBL] [Abstract][Full Text] [Related]
12. Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations.
Fan P; Craig Jordan V
Steroids; 2014 Nov; 90():44-52. PubMed ID: 24930824
[TBL] [Abstract][Full Text] [Related]
13. Effects of oral estrogen, raloxifene and arzoxifene on gene expression in serotonin neurons of macaques.
Bethea CL; Mirkes SJ; Su A; Michelson D
Psychoneuroendocrinology; 2002 May; 27(4):431-45. PubMed ID: 11911997
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer chemoprevention: a review of selective estrogen receptor modulators.
Johansen AM
Clin J Oncol Nurs; 2005 Jun; 9(3):317-20. PubMed ID: 15973842
[TBL] [Abstract][Full Text] [Related]
15. Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs).
Musa MA; Khan MO; Cooperwood JS
Curr Med Chem; 2007; 14(11):1249-61. PubMed ID: 17504144
[TBL] [Abstract][Full Text] [Related]
16. The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells.
Freddie CT; Larsen SS; Bartholomaeussen M; Lykkesfeldt AE
Mol Cell Endocrinol; 2004 Apr; 219(1-2):27-36. PubMed ID: 15149724
[TBL] [Abstract][Full Text] [Related]
17. Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy.
Licun W; Tannock IF
Clin Cancer Res; 2003 Oct; 9(12):4614-8. PubMed ID: 14555537
[TBL] [Abstract][Full Text] [Related]
18. Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats.
Wu X; Glinn MA; Ostrowski NL; Su Y; Ni B; Cole HW; Bryant HU; Paul SM
Brain Res; 1999 Nov; 847(1):98-104. PubMed ID: 10564741
[TBL] [Abstract][Full Text] [Related]
19. Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade.
Gajdos C; Jordan VC
Clin Breast Cancer; 2002 Jan; 2(4):272-81. PubMed ID: 11899358
[TBL] [Abstract][Full Text] [Related]
20. Selective estrogen receptor modulators: an update on recent clinical findings.
Shelly W; Draper MW; Krishnan V; Wong M; Jaffe RB
Obstet Gynecol Surv; 2008 Mar; 63(3):163-81. PubMed ID: 18279543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
